Technical Analysis for TERN - Terns Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 8.17 8.36% 0.63
TERN closed up 8.36 percent on Wednesday, July 28, 2021, on 39 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Down Down
Historical TERN trend table...

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 8.36%
New 52 Week Low Weakness 8.36%
Wide Bands Range Expansion 8.36%
Down 3 Days in a Row Weakness 8.36%
Down 4 Days in a Row Weakness 8.36%
Down 5 Days in a Row Weakness 8.36%
Older End-of-Day Signals for TERN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 13 hours ago
Possible NR7 about 15 hours ago
Rose Above Previous Day's High about 19 hours ago
Up 5% about 19 hours ago
Up 3% about 19 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Terns Pharmaceuticals, Inc. Description

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase 2a clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase 1 clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability; and GLP-1R, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to address metabolic processes involved in the pathogenesis of NASH. Terns Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Foster City, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Steatohepatitis Hepatitis Non Alcoholic Fatty Liver Disease Peptide Hormones Liver Bile Acid Anti Diabetic Drugs Chronic Liver Diseases Glucagon Glucagon Like Peptide 1 Receptor

Is TERN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 28.36
52 Week Low 7.38
Average Volume 75,638
200-Day Moving Average 0.00
50-Day Moving Average 13.26
20-Day Moving Average 9.64
10-Day Moving Average 8.59
Average True Range 0.82
ADX 44.45
+DI 9.77
-DI 35.97
Chandelier Exit (Long, 3 ATRs) 11.23
Chandelier Exit (Short, 3 ATRs) 9.83
Upper Bollinger Bands 12.34
Lower Bollinger Band 6.94
Percent B (%b) 0.23
BandWidth 56.06
MACD Line -1.59
MACD Signal Line -1.62
MACD Histogram 0.0305
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.13
Resistance 3 (R3) 9.05 8.66 8.97
Resistance 2 (R2) 8.66 8.41 8.70 8.92
Resistance 1 (R1) 8.41 8.26 8.54 8.49 8.86
Pivot Point 8.02 8.02 8.08 8.06 8.02
Support 1 (S1) 7.77 7.77 7.90 7.85 7.48
Support 2 (S2) 7.38 7.62 7.42 7.42
Support 3 (S3) 7.13 7.38 7.37
Support 4 (S4) 7.21